New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
16:22 EDTARO, SIRI, CELG, SBUX, LMCA, ULTA, GMCROn The Fly: Closing Wrap
Stocks on Wall Street were lower following another session dominated by headlines concerning the geopolitical situation. Stocks were lower early in the session following the lower than expected University of Michigan consumer confidence reading. The market moved in a narrow range and crossed back and forth across the flat-line several times. Investors remain on edge following several recent poor economic reports out of China and frequent remainders of the upcoming elections in the Ukraine on Sunday. ECONOMIC EVENTS: In the U.S., producer prices fell 0.1% overall in February, versus an expected increase of 0.2%. The core reading, which excludes food and energy, fell 0.2%, versus an expected increase of 0.1%. The Reuters/University of Michigan Consumer Sentiment Survey for March unexpectedly dropped to a four-month low of 79.9. The preliminary reading for the month was expected by analysts to have come in at 81.8, which would have been a slight bump from the prior 81.6 figure. In Europe, citizens of the Crimea region of the Ukraine are likely to vote to secede this weekend, even as Ukraine, the U.S and the European Union maintain that the vote is illegal. U.S. Secretary of State John Kerry said he was told that Vladimir Putin is not prepared to make any decision regarding Ukraine until after the country's referendum. COMPANY NEWS: Liberty Media (LMCA) shares gained $9.11, or 7.22%, to $135.25 after the company announced last night that it plans to reclassify its common stock into two tracking stocks, one called Liberty Media Group and the other called Liberty Broadband Group. Liberty President & CEO Greg Maffei called the move "another step in Liberty’s process of offering investors greater choice, transparency and focus." Liberty said in conjunction with the plan that it would drop plans to buy the rest of Sirius XM (SIRI), in which it currently holds a 53% stake in. Sirius XM had previously suspended its stock repurchase program in connection with Liberty Media's proposal and it announced today that it now intends to resume the repurchase plan. Shares of Sirius advanced 7c, or 2.08%, to $3.44 following the news. MAJOR MOVERS: Among the notable gainers was beauty retailer Ulta Salon (ULTA), which advanced $5.75, or 6.42%, to $95.26 after the company’s fourth quarter results beat estimates. Also higher were shares of single-serve coffee machine maker Keurig Green Mountain (GMCR), which rose $7.09, or 6.68%, to $113.25 after the company agreed to new terms in its deal with coffee giant Starbucks (SBUX). Among the noteworthy losers was teen retailer Aeropostale (ARO), which dropped $1.47, or 20.14%, to $5.83 after its fourth quarter results and first quarter outlook missed analysts' consensus expectations and the company entered a financing deal with private equity firm Sycamore Partners. Also lower were shares of drug maker Celgene (CELG), which dropped $6.59, or 4.22%, to $149.41 after the U.K.'s healthcare guidance body issued new draft guidance on the use of the company's Revlimid drug. INDEXES: The Dow fell 43.22, or 0.27%, to 16,065.67, the Nasdaq dropped 15.02, or 0.35%, to 4,245.40, and the S&P 500 declined 5.21, or 0.28%, to 1,841.13.
News For LMCA;SIRI;GMCR;SBUX;ARO;ULTA;CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 10, 2014
10:20 EDTULTAOptions with decreasing implied volatility
Subscribe for More Information
December 9, 2014
14:10 EDTCELGCelgene ISTODAX combination demonstrates complete response in 51% of patients
Subscribe for More Information
08:34 EDTCELGCelgene price target raised to $130 from $102 at Argus
Argus hiked its price target on Celgene as the firm thinks the company posted solid Q3 results, while it is continuing to make progress in its pipeline. Argus keeps a Buy rating on the shares.
08:28 EDTCELGCelgene price target raised to $130 from $112 at UBS
Subscribe for More Information
07:44 EDTCELGAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:55 EDTSIRIStocks with implied volatility movement; CME SIRI
Subscribe for More Information
05:46 EDTCELGCelgene presents POMALYST/IMNOVID Phase IIIb study results at ASH meeting
Celgene announced that results from the STRATUS trial, a single-arm phase IIIb study of pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society of Hematology annual meeting. Pomalidomide is marketed as POMALYST in the United States and IMNOVID in the European Union. In the study, 599 patients with refractory, or relapsed and refractory, disease who had previously failed lenalidomide and bortezomib had been enrolled at the time of the data cutoff. The primary endpoint was safety, and key secondary endpoints included pomalidomide exposure, overall response rate, or ORR, duration of response, or DOR, progression-free survival, or PFS, overall survival, or OS, and cytogenetic analyses. Patients had a median five prior therapies. All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent. At a median follow-up of 6.8 months with a median four cycles received, the median PFS and OS were 4.2 months and 11.9 months, respectively. The ORR was 35%, with 8% of patients achieving at least a very good partial response, or VGPR. The median DOR was 6.8 months. In patients refractory to prior lenalidomide or lenalidomide and bortezomib, similar PFS, OS, and ORR were achieved.
05:22 EDTCELGCelgene reports REVLIMID study data suggests improved response rates, PFS, OS
Subscribe for More Information
05:17 EDTCELGCelgene reports Vidaza Phase III study shows doubled overall survival times
Subscribe for More Information
December 8, 2014
14:06 EDTCELGCelgene reports luspatercept, sotatercept increased hemoglobin levels in trials
Subscribe for More Information
13:54 EDTCELGCelgene announces results from phase lll Revlimid study
Subscribe for More Information
10:20 EDTULTAOptions with decreasing implied volatility
Subscribe for More Information
07:52 EDTSBUXStarbucks price target raised to $97 from $88 at Jefferies
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
06:47 EDTSBUXStarbucks coverage resumed with a Conviction Buy at Goldman
Subscribe for More Information
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
December 7, 2014
16:40 EDTCELGAgios announces new data from Ongoing Phase 1 trial of AG-221
Subscribe for More Information
14:10 EDTCELGAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:16 EDTCELGCelgene, Acceleron announced data from luspatercept phase 2 clinical trial
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use